ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2842

Usefulness of Polymerase Chain Reaction for Diagnosing Whipple’S Disease in Rheumatology

Marion Herbette1, Jean Baptiste Cren2, Laurie Joffres3, charlotte lucas4, Emilie Ricard5, Carine Salliot6, Jerome Guinard7, Aleth Perdriger8, Elisabeth Solau-Gervais9, Béatrice Bouvard10 and Alain Saraux11, 1Rheumatology, University Hospital, Brest, France, 2Rheumatology, University Hospital of Angers, Angers, France, 3University Hospital de Poitiers, Poitiers, France, 4Rheumatology, University Hospital, Rennes, France, 5Rheumatology, University Hospital, Orléans, France, 6department of Rheumatology, Orleans, France, 7Microbiology, CHU Angers, Angers, France, 8Service de Rhumatologie, CHRU de Rennes, Rennes, France, 9Rhumatologie, University Hospital, Poitiers, France, 10rheumatology, CHU Angers, Angers, France, 11Rheumatology, Brest University Medical School Hospital, Brest, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Arthritis, diagnosis, Infection, polymerase chain reaction (PCR) and test

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Infection-related Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Whipple’s disease should be considered in patients with recurrent episodes of seronegative arthritis in the large limb, various symptoms (fever, uveitis,…) or biological abnormalities (eosinophilia, C-reactive protein elevation, anaemia, thrombocytosis…) but none of these findings is specific. To determine when Tropheryma whipplei polymerase chain reaction (PCR) is appropriate in patients evaluated for rheumatological symptoms.

Methods: In a retrospective observational study done in five hospitals, we assessed the clinical and radiological signs that prompted T. whipplei PCR testing between 2010 and 2014, the proportion of patients diagnosed with Whipple’s disease, the number of tests performed and the number of diagnoses according to the number of tests, the patterns of Whipple’s disease, and the treatments used. Diagnosis of Whipple’s disease was based on 1- at least one suggestive clinical finding; 2- at least one positive PCR test; and 3- a dramatic response to antibiotic therapy. There were divided in: CWD: Classic Whipple’s disease (duodenal biopsy PAS staining + or T. whipplei immunohistochemistry, or as blood positive by PCR); FWD: Focal Whipple’s disease (joint fluid positive by PCR but duodenal biopsy negative by PAS staining and immunohistochemistry); CTWAA: Chronic T. whipplei-associated arthritis (duodenal biopsy, stool, or saliva positive by PCR but duodenal biopsy and joint fluid negative).

Results: At least one PCR test was performed in each of 267 patients. Rheumatic signs were peripheral arthralgia (n=239, 89%), peripheral arthritis (n=173, 65%), and inflammatory back pain (n=85, 32%). The main extra-articular signs were constitutional symptoms (n=111, 41.8%), diarrhoea (n=70, 26.5%), fever (n=53, 20%), lymphadenopathy (n=14, 5.3%), and neurological signs (n=11, 4.2%). Whipple’s disease was diagnosed in 13 patients (4.9%). The main samples tested and the more frequently positive tests in the centres with diagnoses of Whipple’s disease were saliva and stool. In the centres with no diagnoses of Whipple’s disease, arthritis was less common, whereas constitutional symptoms, fever, and lymphadenopathy were more common. 11 patients with Whipple’s disease had CRP elevation. The annual incidence ranged across centres from 0 to 3.6/100000 inhabitants. The group with Whipple’s disease had a higher proportion of males, older age, and greater frequency of arthritis. When both stool and saliva PCR are positive the predictive value is 91%. When both stool and saliva PCR are negative the negative predictive value is 99%.

Conclusion: Males aged 40-75 years with unexplained intermittent seronegative peripheral polyarthritis, including those without constitutional symptoms, should have T. whipplei PCR tests on saliva, stool and, if possible, joint fluid. When both stool and saliva PCR are positive the positive predictive value is 91%.


Disclosure: M. Herbette, None; J. B. Cren, None; L. Joffres, None; C. lucas, None; E. Ricard, None; C. Salliot, None; J. Guinard, None; A. Perdriger, None; E. Solau-Gervais, None; B. Bouvard, None; A. Saraux, None.

To cite this abstract in AMA style:

Herbette M, Cren JB, Joffres L, lucas C, Ricard E, Salliot C, Guinard J, Perdriger A, Solau-Gervais E, Bouvard B, Saraux A. Usefulness of Polymerase Chain Reaction for Diagnosing Whipple’S Disease in Rheumatology [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/usefulness-of-polymerase-chain-reaction-for-diagnosing-whipples-disease-in-rheumatology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/usefulness-of-polymerase-chain-reaction-for-diagnosing-whipples-disease-in-rheumatology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology